Cardio-respiratory interaction and autonomic dysfunction in obesity.
I Tonhajzerova1, M Javorka, Z Trunkvalterova
1Institute of Physiology, Jessenius Faculty of Medicine, Comenius University, Martin Faculty Hospital, Martin, Slovakia. tonhajzerova@jfmed.uniba.sk
Summary
Obese adolescents show reduced cardiac vagal control, indicated by lower heart rate variability. This suggests early autonomic dysfunction in pediatric obesity, highlighting potential diagnostic insights.
Area of Science:
- Cardiology
- Pediatrics
- Autonomic Neuroscience
Background:
- Obesity in adolescents is a growing concern.
- Autonomic dysfunction may be an early complication of pediatric obesity.
- Cardio-respiratory interactions offer insights into autonomic control.
Purpose of the Study:
- To investigate cardiovagal dysfunction in obese adolescents.
- To assess heart rate variability (HRV) and blood pressure variability (BPV) in obese vs. control adolescents.
- To determine if respiratory maneuvers reveal autonomic dysfunction.
Main Methods:
- Analysis of heart rate variability (HRV) and blood pressure variability (BPV) spectral power.
- Measurement of high-frequency HRV as an index of cardiac vagal control (respiratory sinus arrhythmia).
- Application of deep breathing and Valsalva maneuver tests.
Main Results:
- Obese adolescents exhibited significantly reduced high-frequency HRV.
- No significant differences in high-frequency BPV were observed between groups.
- Reduced respiratory sinus arrhythmia suggests impaired vagal modulation in obese youth.
Conclusions:
- Obese adolescents demonstrate cardiovagal dysfunction.
- Reduced HRV is a potential early marker for subclinical autonomic dysfunction in pediatric obesity.
- Cardio-respiratory interaction analysis is valuable for diagnosing autonomic dysfunction in obese youth.
Related Concept Videos
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:18Disorders of the Autonomic Nervous System
The autonomic nervous system (ANS) is an intricate network of nerves that controls functions such as the regulation of heart rate, digestion, and blood pressure regulation. When this system malfunctions, it can lead to various disorders that affect multiple bodily functions. One common feature of many autonomic disorders is the involvement of smooth blood vessels, which play a crucial role in regulating blood flow throughout the body.
Raynaud's disease, also known as Raynaud's phenomenon, is a...
Raynaud's disease, also known as Raynaud's phenomenon, is a...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...